Retatrutide is a multi-agonist peptide that simultaneously activates GLP-1, GIP and glucagon receptors.
Recommended for:
Clinical trials have demonstrated that Retatrutide can reduce body weight by up to 24%, improve insulin sensitivity, and lower HbA1c levels.
Indicated for obesity treatment, improvement of glycaemic control in type 2 diabetes, metabolic normalisation, and reduction of cardiovascular risk.
Administered subcutaneously after reconstitution of the lyophilised powder with solvent. The dosage and treatment regimen must be determined individually by a healthcare professional.
Contraindications:
Side effects:









